Dimension Therapeutics
acquired by Ultragenyx PharmaceuticalCambridge, US · Founded 2013 · Delaware corporation · 3 known investors
Find your way into Dimension Therapeutics
Acquired by Ultragenyx Pharmaceutical October 2017 · $152.3M ($6.00 per share, approximately $152.3 million in cash) · source ↗
Dimension Therapeutics was a Cambridge, Massachusetts biopharmaceutical company developing AAV-based gene therapies for rare liver-associated metabolic diseases like hemophilia, OTC deficiency, and glycogen storage disease.
Founders & leadership
AJ
Annalisa JenkinsExecutive
Board
BA
Benjamin AuspitzBoard director
DJ
Donald J. HaydenBoard director
AF
Allan FoxBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$89.5M disclosed across 2 rounds · 2013–2015
▶$65MraisedApr 2015 · 12 investors · BiotechnologyRule 506(b)
▶$65MraisedApr 2015 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rishi GuptaDirector
- Donald J. Hayden, Jr.Director
- Benjamin AuspitzDirector
- Jay K. HachigianExecutive Officer
- Annalisa JenkinsExecutive Officer, Director
- Offering amount
- $65M
- Amount sold
- $65M
- First sale
- Apr 2015
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$24.5MraisedFeb 2015 · 2 investors · Other TechnologyRule 506(b)
▶$24.5MraisedFeb 2015 · 2 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Donald J. HaydenDirector
- Benjamin AuspitzDirector
- Annalisa JenkinsExecutive Officer, Director
- Allan FoxDirector
- Offering amount
- $24.5M
- Amount sold
- $24.5M
- First sale
- Oct 2013
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Dimension Therapeutics do?
- Dimension Therapeutics was a Cambridge, Massachusetts biopharmaceutical company developing AAV-based gene therapies for rare liver-associated metabolic diseases like hemophilia, OTC deficiency, and glycogen storage disease.
- Who are Dimension Therapeutics's investors?
- Dimension Therapeutics's investors include F-Prime Capital, New Leaf Venture Partners, OrbiMed.
- How much funding has Dimension Therapeutics raised?
- Dimension Therapeutics has disclosed $89.5M raised across 2 rounds.
- Who acquired Dimension Therapeutics?
- Dimension Therapeutics was acquired by Ultragenyx Pharmaceutical.
- Where is Dimension Therapeutics headquartered?
- Dimension Therapeutics is headquartered in Cambridge, US.